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s it Time to Expand the Use
f Cardiac Resynchronization
herapy to Patients With
ildly Symptomatic
eart Failure?*
erek V. Exner, MD, MPH
algary, Alberta, Canada
ardiac resynchronization therapy (CRT) is central to the
anagement of patients with highly symptomatic systolic heart
ailure and delayed ventricular conduction. Improved survival
nd reduced rates of hospital stay for heart failure with CRT
ersus standard medical therapy have been documented in
rior trials (1). Thus, CRT combined with a pacemaker or
mplantable cardioverter-defibrillator (CRT-D) is now rou-
inely recommended for patients with New York Heart Asso-
iation (NYHA) functional class III or IV limitation, a QRS
uration 120 ms, and left ventricular (LV) ejection fraction
0.35 despite optimal pharmacologic therapy (2–4).
See page 1837
ationale for CRT earlier in heart failure. Cardiac re-
ynchronization therapy has favorable hemodynamic, ener-
etic, anatomic, and basic cellular effects in advanced heart
ailure (5–8). Thus, it is both plausible and attractive that
arly intervention with CRT in heart failure might delay or
revent disease progression. Yet, although CRT is central to
he management of patients with highly symptomatic sys-
olic heart failure, its role in patients with mildly symptom-
tic heart failure is less certain (1).
V reverse remodeling and clinical outcome. It has been
hown that favorable LV reverse remodeling is associated with
mproved long-term clinical outcomes with CRT (9). How-
ver, it is important to recognize that LV reverse remodeling is
ot a perfect surrogate for clinically important long-term
utcomes. For example, the relationship between the degree of
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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edtronic and St. Jude Medical, honoraria from Boston Scientific, and research
upport from Sorin/ELA.V reverse remodeling and a long-term survival benefit from
RT is far from clear when patients with an ischemic versus
onischemic etiology of heart failure are considered (Table 1)
10–16). For example, in both the MIRACLE (Multicenter
nSync Randomized Clinical Evaluation) (10,11) and the
ARE HF (CArdiac REsynchronisation in Heart Failure
tudy) (15,16) studies patients with an ischemic etiology of
eart failure had less LV reverse remodeling than those with a
onischemic etiology. Yet, the survival benefit from CRT was
quivalent in patients with ischemic and nonischemic heart
ailure. Furthermore, despite the fact that patients with isch-
mic heart failure typically have less LV reverse remodeling
ith CRT than patients with nonischemic heart failure (Table
), the survival benefit with CRT tended to be greater in
atients with an ischemic versus nonischemic etiology of heart
ailure in the COMPANION (Comparison of Medical Ther-
py, Pacing, and Defibrillation in Heart Failure) trial (14).
hus, although favorable LV remodeling is desirable with
RT, it does not provide the complete answer with respect to
he long-term clinical benefit from CRT.
RT in patients with mild heart failure symptoms. Until
ecently, few studies evaluated the efficacy of CRT in
atients with mild heart failure (NYHA functional class I or
I). These initial studies suggested that CRT had only a
inor effect on preventing heart failure hospital stay and
as not associated with a significant effect on mortality (1).
able 2 summarizes completed and ongoing trials evaluat-
ng the efficacy of CRT in patients with mildly symptomatic
eart failure. The CONTAK CD (Guidant Corporation,
t. Paul, Minnesota) study represents the earliest of these
12). In that trial, patients with mostly NYHA functional
lass III or IV limitation underwent CRT-D implantation.
uring the post-implant period, before randomization,
atients had more intensive medical therapy for their heart
ailure. This resulted in a substantial number of patients
aving improved NYHA functional class at the time of
andomization to active CRT (CRT ON) or usual care
CRT OFF). The CRT did not significantly alter the
rimary end point of CONTAK CD, progression of heart
ailure. However, greater LV reverse remodeling was ob-
erved with CRT versus control, both in patients with
dvanced NYHA functional class limitation and those with
ildly symptomatic heart failure. The MIRACLE ICD II
Multicenter InSync ICD Randomized Clinical Evaluation
I) study (17) included only patients with NYHA functional
lass II symptoms. The primary efficacy end point for
IRACLE ICD II, change in peak oxygen uptake from baseline
o 6 months, was not significantly altered with CRT. However,
RT did favorably alter the secondary outcomes of LV reverse
emodeling and clinical response. These early studies were
ollowed by the much larger REVERSE (Resynchronization
everses Remodeling in Systolic Left Ventricular Dysfunc-
ion) trial (18). The REVERSE trial included 610 patients
ith mostly NYHA functional class II limitation. The
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Cardiac Resynchronization Therapy November 10, 2009:1847–9atients who worsened, was not significantly different in the
RT ON versus CRT OFF group over 12 months of
ollow-up. However, CRT was associated with a significant
eduction in the pre-specified secondary end point left
entricular end-systolic volume index (LVESVi). The re-
uction in LVESVi was particularly prominent in patients
ith a nonischemic etiology of heart failure, those with
arger LV end systolic volumes, and patients with wider
RS values (152 ms) at baseline. The time to first heart
ailure hospital stay was delayed to a greater extent in
atients randomized to CRT ON versus CRT OFF (p 
.03). The mixed results from the REVERSE study indi-
ate that, although CRT might slow the progression of
eart failure, as measured by changes in LV remodeling, its
mpact on clinical outcomes over the near term seem
odest. Thus, larger and longer-term studies are required to
etter define the role of CRT in less symptomatic patients.
esults in the REVERSE European cohort. The sub-
nalysis of European data from the REVERSE trial by
aubert et al. (19) in this issue of the Journal provides
mportant additional insights into the role of CRT in
atients with mild symptoms of heart failure. Their analysis
ncluded the 262 patients who received CRT devices in
urope. As in the main REVERSE study, European
articipants were required to have a QRS width 120 ms
nd LV ejection fraction of 0.40. Participants were
andomly assigned in a 2:1 manner to active therapy (CRT
ey Randomized Trials Assessing the Efficacy of CRT: Ischemic VeTable 1 Key Randomized Trials Assessing the Efficacy of CRT:
Study (Ref. #) Year n Ischemic Etiology LV Reve
MIRACLE (10,11) 2002 453 54%
CONTAK CD (12) 2003 490 69%
MIRACLE ICD (13) 2003 369 70%
COMPANION (14) 2004 1,520 55%
CARE HF (15,16) 2005 812 42%
RT  Cardiac Resynchronization Therapy; LV  left ventricular; —  not reported;   no impr
ey Randomized Trials Assessing the Efficacy of CRT in Patients WTable 2 Key Randomized Trials Assessing the Efficacy of CRT i










MIRACLE ICD II (17) 2004 186 II: 100% 186
REVERSE (18) 2008 610 I: 18%
II: 82%
610
MADIT CRT (20) 2009 1,820 I: 15%
II: 85%
1,820
RAFT (21) 2010 1,800 — —VEF  left ventricular ejection fraction; NYHA  New York Heart Association; other abbreviations as in TN, n  180) or control (CRT OFF, n  82). European
atients were followed for 24 months, twice the duration of
he North American cohort. Over 24 months, 19% of the
RT ON versus 34% of the CRT OFF patients worsened
p  0.01). Furthermore, LVESVi decreased by a mean of
7.5  31.8 ml/m2 in the CRT ON versus only 2.7  25.8
l/m2 in the CRTOFF group (p 0.0001). The time to first
eart failure hospital stay or death was also significantly delayed
ith CRT ON versus CRT OFF (p  0.003). Thus, these
esults provide additional data to support the use of CRT in
elaying heart failure progression.
he REVERSE European cohort data in perspective.
lthough the data from Daubert et al. (19) are interesting,
hey should not be considered definitive. First, it is impor-
ant to recognize that few patients were truly asymptomatic
nd the results are mostly applicable to patients with mildly
ymptomatic heart failure. Furthermore, as with any sub-
nalysis, there is the distinct possibility of overestimating or
nderestimating the true effect size by chance alone. This is
articularly relevant, given that only 13 deaths were ob-
erved in the entire European cohort.
As acknowledged by the authors, important differences in
emographic characteristics were apparent between the
uropean and North American patients. Furthermore, these
ight in part explain the apparent differences in CRT efficacy
n this subanalysis. European patients were less likely to have
n ischemic etiology of heart failure, had longer average QRS
Nonischemic Etiology of Heart Failuremic Versus Nonischemic Etiology of Heart Failure
Efficacy of CRT
modelling Survival Differences by Etiology of Heart Failure
 Less remodeling among patients with ischemic
etiology. No reported differences in survival.
 No reported differences in remodeling or survival.
 No reported differences in remodeling or survival.
 Statistical trend (p  0.06) toward a greater
reduction in mortality in patients with an
ischemic versus a nonischemic etiology.
 Less remodeling among patients with ischemic
etiology but similar survival benefit.
t;   small improvement;   large improvement.
ess Symptomatic Heart Failuretients With Less Symptomatic Heart Failure









— —   
370 0.25   
399 0.27   
361 0.24   
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on-European participants in the REVERSE study. Thus, the
uthor’s conclusion, “these observations suggest that CRT
revents the progression of disease in patients with asymptom-
tic or mildly symptomatic LV dysfunction,” is generally
easonable. However, it is important to acknowledge that
dditional evidence is required before more wide-scale use of
RT in patients with mildly symptomatic heart failure.
ngoing and recently completed trials. Two large trials
ill provide important additional evidence of the efficacy of
RT in a broader group of patients with mildly symptomatic
eart failure. The MADIT CRT (Multi-center Automatic
efibrillator Implantation with Cardiac Resynchronization
herapy) study compared usual implantable cardioverter-
efibrillator therapy with CRT-D in 1,820 subjects in sinus
hythm with LV ejection fraction values 0.30, QRS dura-
ions130 ms, and mild heart failure. This trial demonstrated
29% reduction in the risk of the combined end point of death
r heart failure events (p  0.003) (20). This outcome was
urely driven by a reduction in heart failure events. The
roportion of these events that were actual hospitalizations for
eart failure is unclear. Further, the average 6-min walk test
istance of 361  108 m suggests that many of these patients
ould have been categorized as NYHA functional class III in
ast trials, based on a walk distance of 450 m (10). None-
heless, clear improvements in LV mechanical indexes and
orresponding reductions in heart failure events were demon-
trated in MADIT-CRT. The RAFT (Resynchronization/
efibrillation in Advanced Heart Failure Trial) is another
arge ongoing study comparing implantable cardioverter-
efibrillator therapy with CRT-D among 1,800 subjects in
inus rhythm or with atrial fibrillation, LV ejection fractions
0.30, QRS durations 120 ms, and mostly mildly symp-
omatic heart failure (21). The REVERSE study and other
rials will provide clearer answers as to the role of CRT in patients
ith mildly symptomatic heart failure. Given the growing evi-
ence for CRT as a means to delay heart failure progression, it is
empting to recommend it beyond present guidelines (2–4).
owever, it is premature to recommend CRT as a routine
ntervention to patients with asymptomatic LV dysfunction or
hose with mildly symptomatic heart failure today.
eprint requests and correspondence:Dr. Derek V. Exner, 3330
ospital Drive Northwest, Room G208, Calgary, Alberta T2N
N1, Canada. E-mail: exner@ucalgary.ca.
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